NEW

Italians Share Novel Operating Room Research Using UVDI-360 Room Sanitizer

UltraViolet Devices Inc. (UVDI) has announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at this month’s Society for Healthcare Epidemiology of America (SHEA) Spring Conference.

The Joint Commission issues Sentinel Event Alert on optimizing medication safety with smart infusion pumps

A new Sentinel Event Alert from The Joint Commission, “Optimizing smart infusion pump safety with DERS,” describes how built-in dose error reduction software (DERS) can improve patient safety.

Hensler Bone Press Receives CE Certification

Hensler Surgical Technologies has announced its newly obtained CE mark for the Hensler Bone Press (HBP).

Healthmark Offers New Anti-Fatigue Mat

Healthmark Industries has introduced an Anti-Fatigue Mat to its Personal Protection Equipment (PPE) product line.

Diversey Announces MoonBeam3 Effective Against SARS-CoV-2 in Seconds

Diversey, Inc. has received confirmation through third-party testing that MoonBeam3 UV-C disinfection technology is effective in just seconds against SARS-CoV-2, which causes COVID-19.

MoonBeam3 is an ultraviolet-C disinfection device that adds assurance beyond manual cleaning and disinfection. This portable, powerful solution disinfects quickly, reliably and responsibly. MoonBeam3 is cost-effective and designed for fast disinfection of public and high-risk areas. The system offers three individually adjustable arms that can be positioned at almost any angle, optimizing disinfection energy to allow dosing of both horizontal and vertical surfaces, in just 3 minutes.

MoonBeam3 has undergone third-party testing against several microorganisms including enveloped viruses, small non-enveloped viruses, bacteria and bacterial spores. These tests have demonstrated a significant log reduction in these key pathogens.

Since studies have shown that contamination of environmental surfaces in health care facilities with SARS-CoV-2 viral RNA is widespread, Diversey commissioned third-party testing of MoonBeam3 in the U.S., and has also partnered with the highly respected Fujita Health University in Japan, to test the effectiveness of the MoonBeam3 against SARS-CoV-2. The completed test results from Japan proved that MoonBeam3 was effective against SARS-CoV-2 under a range of conditions with contact times as low as 4 seconds for a 6-log reduction.

This study validates that MoonBeam3 is effective against SARS-CoV-2, the pathogen that causes COVID-19.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X